Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
Avenue Therapeutics, Inc. (Nasdaq: ATXI), a specialty pharmaceutical company focusing on neurologic disease treatments, has announced its participation in Maxim Group's 2024 Healthcare Virtual Summit.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Avenue Therapeutics, Inc. (Nasdaq: ATXI), a specialty pharmaceutical company focusing on neurologic disease treatments, has announced its participation in Maxim Group's 2024 Healthcare Virtual Summit. The company's CEO, Alexandra MacLean, M.D., will engage in a fireside chat on Tuesday, October 15, 2024, at 1:30 PM ET.
The event will be accessible to registered attendees, and investors can sign up or log in to the conference through a provided link. This participation highlights Avenue Therapeutics' commitment to engaging with the investment community and sharing insights about their developments in the neurologic disease treatment sector.
Details
News Market Reaction – ATXI
The recorded move for ATXI in the trading session of this news was +0.51%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group’s 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET.
The fireside chat will be available to registered attendees. Investors may sign-up or log-in to the conference here.
About Avenue Therapeutics
Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. It is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABAA α2, α3 receptor positive allosteric modulator for CNS diseases, and IV tramadol for the management of acute postoperative pain in adults in a medically supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.avenuetx.com.
Contact:
Jaclyn Jaffe
Avenue Therapeutics, Inc.
(781) 652-4500
ir@avenuetx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.